Stephens raises targets for Anthem, Cigna, peers on HHS rebate rule withdrawal

Following press reports that the White House has withdrawn its proposed rule to eliminate drug rebates in Medicare/Medicaid outside point of sale, Stephens analyst Scott Fidel raised his price targets on a number of managed care stocks, calling the elimination of this key near-term overhang a “material positive event” for the MCO and PBM group. He raised his price target on Anthem (ANTM) to $350 from $335, upped his target on Cigna (CI) to $240 from $225, increased his target on Humana (HUM) to $320 from $300 and raised his target on UnitedHealth (UNH) to $290 from $270. Fidel keeps Overweight ratings on all four of those stocks. He also raised his target on Magellan Health (MGLN) to $74 from $70, though he keeps an Equal Weight rating on that stock, citing the company’s softer fundamentals.